Barely Significant
← all excerpts

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

PLoS One · 2013 · PMC3605436 · PMID 23555589

Europe PMCDOI
1
hedged sentence
0.0008
closest p · 0.0× alpha
0.0008
boldest claim

The sentences

highly significantp<0.0008actually significant
The 6 months results of HRQoL, sleepiness, depression, cognition, disability and walking speed were all highly significant (p<0.0008–0.0001) and consistent with the results at 12 months (data not shown).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.